XML 43 R31.htm IDEA: XBRL DOCUMENT v3.25.2
Segment Reporting (Tables)
6 Months Ended
Jun. 30, 2025
Segment Reporting [Abstract]  
Schedule of Segment Revenue, Segment Profit and Segment Expenses The following table illustrates reported segment revenue, segment profit and significant segment expenses (in thousands):

 

 

Three Months Ended June 30,

 

 

Six Months Ended June 30,

 

 

 

2025

 

 

2024

 

 

2025

 

 

2024

 

NUPLAZID net revenue

 

$

168,479

 

 

$

157,409

 

 

$

328,199

 

 

$

287,332

 

DAYBUE net revenue

 

 

96,087

 

 

 

84,554

 

 

 

180,683

 

 

 

160,462

 

Total revenues

 

 

264,566

 

 

 

241,963

 

 

 

508,882

 

 

 

447,794

 

Less:

 

 

 

 

 

 

 

 

 

 

 

 

Cost of goods sold

 

 

8,384

 

 

 

7,430

 

 

 

17,595

 

 

 

17,504

 

License fees and royalties

 

 

12,350

 

 

 

10,800

 

 

 

23,531

 

 

 

23,677

 

Research and development expense:

 

 

 

 

 

 

 

 

 

 

 

 

External research and development

 

 

54,319

 

 

 

57,381

 

 

 

109,304

 

 

 

98,870

 

Internal costs(1)

 

 

23,632

 

 

 

18,852

 

 

 

46,912

 

 

 

37,042

 

Total research and development expense

 

 

77,951

 

 

 

76,233

 

 

 

156,216

 

 

 

135,912

 

Selling, general and administrative

 

 

133,507

 

 

 

117,063

 

 

 

259,877

 

 

 

225,054

 

Interest income, net

 

 

(7,243

)

 

 

(6,359

)

 

 

(15,144

)

 

 

(11,865

)

Other income

 

 

(594

)

 

 

(386

)

 

 

(1,183

)

 

 

(672

)

Income tax expense

 

 

13,545

 

 

 

3,793

 

 

 

22,337

 

 

 

8,240

 

Consolidated net income

 

$

26,666

 

 

$

33,389

 

 

$

45,653

 

 

$

49,944

 

_______________

(1)
Includes personnel expenses and costs allocated to multiple research and development programs, including benefits, information technology, facilities and inventory.